2013
Meta-Analysis of Everolimus-Eluting Versus Paclitaxel-Eluting Stents in Coronary Artery Disease Final 3-Year Results of the SPIRIT Clinical Trials Program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions)
Dangas GD, Serruys PW, Kereiakes DJ, Hermiller J, Rizvi A, Newman W, Sudhir K, Smith RS, Cao S, Theodoropoulos K, Cutlip DE, Lansky AJ, Stone GW. Meta-Analysis of Everolimus-Eluting Versus Paclitaxel-Eluting Stents in Coronary Artery Disease Final 3-Year Results of the SPIRIT Clinical Trials Program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions). JACC Cardiovascular Interventions 2013, 6: 914-922. PMID: 24050859, DOI: 10.1016/j.jcin.2013.05.005.Peer-Reviewed Original ResearchMeSH KeywordsAgedCardiovascular AgentsCoronary Artery DiseaseCoronary RestenosisCoronary ThrombosisDrug-Eluting StentsEverolimusFemaleHumansKaplan-Meier EstimateMaleMiddle AgedMulticenter Studies as TopicMultivariate AnalysisMyocardial InfarctionPaclitaxelPercutaneous Coronary InterventionProportional Hazards ModelsProsthesis DesignRandomized Controlled Trials as TopicRisk FactorsSirolimusTime FactorsTreatment OutcomeConceptsPaclitaxel-eluting stentsIschemia-driven target lesion revascularizationMajor adverse cardiac eventsAdverse cardiac eventsTarget lesion revascularizationLesion failureMyocardial infarctionLesion revascularizationCause mortalityCardiac eventsStent thrombosisStent typeEvent ratesTarget lesion failureClinical trial programException of diabetesIndividual patient dataIndividual clinical outcomesCardiac deathComposite endpointClinical outcomesSPIRIT IIClinical trialsCoronary implantationTrial program
2011
Impact of Lesion Length and Vessel Size on Clinical Outcomes After Percutaneous Coronary Intervention With Everolimus- Versus Paclitaxel-Eluting Stents Pooled Analysis From the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice) Randomized Trials
Claessen BE, Smits PC, Kereiakes DJ, Parise H, Fahy M, Kedhi E, Serruys PW, Lansky AJ, Cristea E, Sudhir K, Sood P, Simonton CA, Stone GW. Impact of Lesion Length and Vessel Size on Clinical Outcomes After Percutaneous Coronary Intervention With Everolimus- Versus Paclitaxel-Eluting Stents Pooled Analysis From the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice) Randomized Trials. JACC Cardiovascular Interventions 2011, 4: 1209-1215. PMID: 22115661, DOI: 10.1016/j.jcin.2011.07.016.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, Balloon, CoronaryCardiovascular AgentsChi-Square DistributionCoronary AngiographyCoronary StenosisDrug-Eluting StentsEverolimusFemaleHumansKaplan-Meier EstimateMaleMiddle AgedMyocardial InfarctionPaclitaxelPredictive Value of TestsProportional Hazards ModelsProsthesis DesignRandomized Controlled Trials as TopicRisk AssessmentRisk FactorsSeverity of Illness IndexSirolimusThrombosisTime FactorsTreatment OutcomeConceptsMajor adverse cardiac eventsPaclitaxel-eluting stentsReference vessel diameterEverolimus-eluting stentsPercutaneous coronary interventionLong lesionsGroup BLesion lengthMACE rateCoronary interventionSmall vesselsGroup AStent typeShort lesionsAdverse cardiac eventsHigh-risk patientsPatient-level dataLarge vesselsLower ratesCOMPARE trialLesion revascularizationEfficacy outcomesAdverse eventsCardiac eventsIndependent predictors
2010
Side branch occlusion with everolimus-eluting and paclitaxel-eluting stents: three-year results from the SPIRIT III randomised trial.
Lansky AJ, Yaqub M, Hermiller JB, Smith RS, Farhat N, Caputo R, Williams JE, Sanz M, Koo K, Sood P, Sudhir K, Stone GW. Side branch occlusion with everolimus-eluting and paclitaxel-eluting stents: three-year results from the SPIRIT III randomised trial. EuroIntervention 2010, 6 Suppl J: j44-52. PMID: 21930490, DOI: 10.4244/eijv6supja8.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, Balloon, CoronaryCardiovascular AgentsCoronary AngiographyCoronary Artery DiseaseCoronary RestenosisDrug-Eluting StentsEverolimusFemaleHumansKaplan-Meier EstimateMaleMiddle AgedMyocardial InfarctionPaclitaxelProspective StudiesProsthesis DesignRisk AssessmentRisk FactorsSingle-Blind MethodSirolimusTime FactorsTreatment OutcomeUnited StatesConceptsPeriprocedural myocardial infarctionSide branch occlusionBranch occlusionMyocardial infarctionStent placementDrug-eluting stent placementIndependent angiographic core laboratoryPaclitaxel-eluting stent placementLong-term adverse outcomesSPIRIT III trialPaclitaxel-eluting stentsAngiographic core laboratoryThree-year resultsLower ratesSide branchesEES armIII trialsMI ratesIndependent predictorsClinical outcomesAdverse outcomesProcedural angiogramsGrade 0Stent typeCore laboratoryComparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients with two treated vessels: 2-year results from the SPIRIT III randomised trial.
Applegate RJ, Hermiller JJ, Sanz M, Doostzadeh J, Pierson W, Su X, Lansky AJ, Sudhir K, Stone GW. Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients with two treated vessels: 2-year results from the SPIRIT III randomised trial. EuroIntervention 2010, 6: 437-46. PMID: 20884430, DOI: 10.4244/eij30v6i4a75.Peer-Reviewed Original ResearchConceptsPaclitaxel-eluting stentsClinical outcomesStent typeMajor adverse cardiac eventsTwo-year event ratesSPIRIT IIIPaclitaxel-eluting coronary stentsSPIRIT III trialYear clinical outcomesAdverse cardiac eventsCardiac eventsIII trialsPE groupTwo-vesselPatientsEvent ratesCoronary stentsTrialsVessel treatmentStentsOutcomesVesselsSignificant interactionStentingLesionsA pooled gender based analysis comparing the XIENCE V(R) everolimus-eluting stent and the TAXUS paclitaxel-eluting stent in male and female patients with coronary artery disease, results of the SPIRIT II and SPIRIT III studies: two-year analysis.
Seth A, Serruys PW, Lansky A, Hermiller J, Onuma Y, Miquel-Hebert K, Yu S, Veldhof S, Sood P, Sudhir K, Stone GW. A pooled gender based analysis comparing the XIENCE V(R) everolimus-eluting stent and the TAXUS paclitaxel-eluting stent in male and female patients with coronary artery disease, results of the SPIRIT II and SPIRIT III studies: two-year analysis. EuroIntervention 2010, 5: 788-94. PMID: 20142192, DOI: 10.4244/eijv5i7a132.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, Balloon, CoronaryCardiovascular AgentsCoronary AngiographyCoronary RestenosisCoronary StenosisDrug-Eluting StentsEverolimusFemaleHumansKaplan-Meier EstimateMaleMiddle AgedMulticenter Studies as TopicMyocardial InfarctionPaclitaxelProsthesis DesignRandomized Controlled Trials as TopicRetrospective StudiesRisk AssessmentRisk FactorsSex FactorsSingle-Blind MethodSirolimusThrombosisTime FactorsTreatment OutcomeConceptsMajor adverse cardiac eventsPaclitaxel-eluting stentsTAXUS paclitaxel-eluting stentTarget vessel failureAngiographic late lossLate lossDiameter stenosisIII studyPooled analysisSPIRIT IIAdverse cardiac eventsSegment late lossStent late lossCoronary artery diseaseEES groupCardiac eventsArtery diseaseFemale patientsPES groupPatient levelClinical dataXIENCE VStent typeTwo-year analysisWomen